Molecular Cancer Research, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands; Oncode Institute, Utrecht, the Netherlands.
Oncode Institute, Utrecht, the Netherlands; Department of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, Nijmegen, the Netherlands.
Cell Rep. 2018 Feb 6;22(6):1600-1614. doi: 10.1016/j.celrep.2018.01.033.
Organoid technology provides the possibility of culturing patient-derived colon tissue and colorectal cancers (CRCs) while maintaining all functional and phenotypic characteristics. Labeling stem cells, especially in normal and benign tumor organoids of human colon, is challenging and therefore limits maximal exploitation of organoid libraries for human stem cell research. Here, we developed STAR (stem cell Ascl2 reporter), a minimal enhancer/promoter element that reports transcriptional activity of ASCL2, a master regulator of LGR5 intestinal stem cells. Using lentiviral infection, STAR drives specific expression in stem cells of normal organoids and in multiple engineered and patient-derived CRC organoids of different genetic makeup. STAR reveals that differentiation hierarchies and the potential for cell fate plasticity are present at all stages of human CRC development. Organoid technology, in combination with the user-friendly nature of STAR, will facilitate basic research into human adult stem cell biology.
类器官技术提供了培养源自患者的结肠组织和结直肠癌(CRC)的可能性,同时保持所有功能和表型特征。标记干细胞,特别是在人类结肠的正常和良性肿瘤类器官中,具有挑战性,因此限制了类器官文库在人类干细胞研究中的最大利用。在这里,我们开发了 STAR(干细胞 Ascl2 报告基因),这是一个最小的增强子/启动子元件,可报告 ASCL2 的转录活性,ASCL2 是 LGR5 肠干细胞的主要调节因子。使用慢病毒感染,STAR 在正常类器官的干细胞中和多种工程化和源自患者的具有不同遗传构成的 CRC 类器官中特异性表达。STAR 表明,在人类 CRC 发展的所有阶段都存在分化层次结构和细胞命运可塑性的潜力。类器官技术与 STAR 的用户友好性相结合,将促进人类成体干细胞生物学的基础研究。